Treatment Options for Relapsed/Refractory Mantle Cell Lymphoma

Jeremy S. Abramson, MD, MMSc


February 17, 2023

The introduction of Bruton tyrosine kinase (BTK) inhibitors has significantly improved outcomes for patients with relapsed/refractory mantle cell lymphoma (MCL), and these therapies are now widely used.

Newer generations of BTK inhibitors have shown progression-free survival of nearly 3 years as well as improved safety profiles. Unfortunately, progression on BTK inhibitor therapy occurs in most patients.

Chimeric antigen receptor (CAR) T-cell therapy with brexucabtagene autoleucel has emerged as a third-line option, providing a median duration of response of 28 months. Because of the risk for toxicity, however, not all patients are candidates for CAR T-cell therapy.

In this ReCAP, Dr Jeremy Abramson from Massachusetts General Cancer Center in Boston reports on therapeutic options available for patients with relapsed/refractory MCL, including the newly US FDA–approved noncovalent BTK inhibitor pirtobrutinib.

Dr Abramson also discusses emerging treatment options, including combination targeted therapies, bispecific antibodies, and antibody-drug conjugates such as zilovertamab vedotin, which has shown encouraging responses in phase 1 trials.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.